H+/Cl- symport activities,6,7 prodigiosins also bind DNA
effectively8 and facilitate oxidative DNA cleavage in the
presence of copper2+ (Cu(II)).9 The nuclease activity is
thought to occur via π-radical cation formation at the
electron-rich pyrrolylpyrromethene entity. This event could
be stimulated by the interaction of Cu(II) to yield Cu(I),
which is known to foster reductive activation of molecular
oxygen (O2) leading to the formation of a superoxide radical
anion (O2•-) and hence hydrogen peroxide (H2O2). The
interaction of H2O2 with a Cu-bound prodigiosin species10
is thought to initiate DNA cleavage. Structure-activity
relationships demonstrate that replacement of the individual
metal-coordinating pyrrole rings by other weaker Cu(II)-
ligating arenes results in marked loss of nuclease activity
and cytotoxicity.11
Scheme 1. Synthesis of Prodigiosin Analogue 2
Although coordination of 1 to a redox-active metal cation
represents one way of triggering oxidation of the natural
alkaloid, Roth noted that prodigiosins also possess photo-
sensitizing activity.12 Here, exposure of colorless mutant
Sarcina lutea cells to prodigiosin and visible light led to cell
death in an O2-dependent process. Thus, we speculated that
1 would undergo photooxidation to reductively activate O2
and yield prodigiosin-derived π-radical cations that may act
to facilitate tumor destruction. Presently, we report on our
initial findings regarding photoinduced cytotoxicity of pro-
digiosin (1) and the synthetic analogue 2 (Figure 1) against
HL-60 leukemia cancer cells. Our results provide new
insights into the redox properties of prodigiosin analogues
and afford design ideas for their development as photoac-
tivatable anticancer agents.
Although prodigiosin (1) exhibited an increase in cyto-
toxicity when exposed to visible light, the pigment was too
active in the absence of light. Our initial strategy to inhibit
dark cytotoxicity was to replace the A-pyrrole of 1 with an
alternative, nonmetal-coordinating arene.4,12 Scheme 1 shows
the synthesis of the phenyl analogue 2 that was prepared
using the strategies outlined by D’Alessio and Rossi13 (see
Supporting Information for details).
using human promyelocytic leukemia (HL-60) cells. These
cells have been utilized previously by our research group to
determine structure-activity relationships for the prodigio-
sins.10,12b Prodigiosin (1) exhibited an IC50 value of ∼6.6
µM following 4 h of drug exposure. Under analogous
conditions, the synthetic derivative 2 failed to inhibit colony
formation at 25 µM, which was the maximum drug concen-
tration examined (IC50 (dark), see Table 1). The photocyto-
Table 1. Inhibition of HL-60 Cell Growth by Prodigiosinsa
compound
IC50 (dark)
IC50 (light)c
1
2
6.6 ( 0.1
>25b
2.5 ( 0.2
16.2 ( 0.2
a Inhibition of colony formation was assessed using the soft agar
clonogenic survival assay as described in the Supporting Information. Values
in micromolar are expressed as the mean of three determinations. b No
inhibition at 25 µM drug. c Inhibition following 4 h exposure to the drug
in the presence of 30 min exposure to visible light (>495 nm).
The ability of 1 and 2 to inhibit cancer cell growth in the
absence and presence of visible light was then determined
toxicity of 1 and 2 was then determined by exposing HL-60
cells to drug and visible light (λ > 495 nm) for 30 min
followed by incubation for an additional 3.5 h in the absence
of light. Cells exposed to 30 min of light in the absence of
drug showed no inhibition of colony formation. As shown
in Table 1, prodigiosin 1 was more active with irradiation
(IC50 (dark) vs IC50 (light)), as was the derivative 2 (IC50
(light) ) 16.2 µM). These results demonstrated that prodi-
giosin-based pigments can serve as photoactivatable anti-
cancer agents.
To determine how 1 and 2 may stimulate photocytotox-
icity, their photoreactions in buffered water were studied
using absorption spectroscopy and LC-MS for product
analysis. Figure 2 shows the absorption spectra of 1 (7 µM)
and 2 (18 µM) before and after different irradiation times.
For 1 (Figure 2A), the absorption maxima at 538 nm
(6) Sessler, J. L.; Eller, L. R.; Cho, W.-S.; Nicolaou, S.; Aguilar, A.;
Lee, J. T.; Lynch, V. M.; Magda, D. J. Angew. Chem., Int. Ed. 2005, 44,
5989-5992.
(7) (a) Sato, T.; Konno, H.; Tanaka, Y.; Kataoka, T.; Nagai, K.;
Wasserman, H.; Ohkuma, S. J. Biol. Chem. 1998, 273, 21455-21462. (b)
Gale, P. A.; Light, M. E.; McNally, B.; Navakhun, K.; Sliwinski, K. E.;
Smith, B. D. Chem. Commun. 2005, 3773-3775.
(8) (a) Melvin, M. S.; Ferguson, D. C.; Lindquist, N.; Manderville, R.
A. J. Org. Chem. 1999, 64, 6861-6869. (b) Montaner, B.; Castillo-AÄ vila,
W.; Martinell, M.; O¨ llinger, R.; Aymami, J.; Giralt, E.; Pe´rez-Toma´s, R.
Toxicol. Sci. 2005, 85, 870-879.
(9) (a) Melvin, M. S.; Tomlinson, J. T.; Saluta, G. R.; Kucera, G. L.;
Lindquist, N.; Manderville, R. A. J. Am. Chem. Soc. 2000, 122, 6333-
6334. (b) Melvin, M. S.; Wooton, K E.; Rich, C. C.; Saluta, G. R.; Kucera,
G. L.; Lindquist, N.; Manderville, R. A. J. Inorg. Biochem. 2001, 87, 129-
135.
(10) Park, G.; Tomlinson, J. T.; Melvin, M. S.; Wright, M. W.; Day, C.
S.; Manderville, R. A. Org. Lett. 2003, 5, 113-116.
(11) (a) Fu¨rstner, A.; Grabowski, E. J. ChemBioChem 2001, 9, 706-
709. (b) Melvin, M. S.; Tomlinson, J. T.; Park, G.; Day, C. S.; Saluta, G.
R.; Kucera, G. L.; Manderville, R. A. Chem. Res. Toxicol. 2002, 15, 734-
741.
decreased together with the shoulder at 487 nm (ꢀ487/ꢀ538
)
(12) Roth, M. M. Photochem. Photobiol. 1967, 6, 923-926.
(13) D’Alessio, R.; Rossi, A. Synlett 1996, 513-514.
0.74) by 38% following 30 min. For 2 (Figure 2B), the
4952
Org. Lett., Vol. 8, No. 21, 2006